Amycretin: Novo Nordisk's Oral GLP-1 and Amylin Dual Agonist — Research Profile 2026

# Amycretin: Novo Nordisk's Oral GLP-1 and Amylin Dual Agonist — Research Profile 2026

Disclaimer: This article is for research and educational purposes only. Amycretin is an investigational compound that has not received FDA approval. Research into amycretin is ongoing. This profile is intended for researchers and scientists studying dual-receptor agonist pharmacology and next-generation obesity therapeutics.

---

Overview

Amycretin is a first-in-class, unimolecular co-agonist developed by Novo Nordisk that simultaneously activates two complementary metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the amylin receptor (AMYR-1). Unlike Novo Nordisk's CagriSema — a combination of two separate molecules (semaglutide and cagrilintide) — amycretin is a single molecule engineered to engage both receptor pathways in a co-formulated, once-daily oral tablet (as well as a once-weekly subcutaneous injection.

Early clinical data from Phase 1 (oral formulation) and Phase 1b/2a (subcutaneous formulation) trials have been described by Novo Nordisk executives as "remarkable," with oral amycretin achieving 13.1% weight loss in 12 weeks in Phase 1 — a result that substantially exceeded semaglutide's weight loss at the same time point in clinical trials.

Based on these results, Novo Nordisk advanced amycretin into Phase 3 clinical development for obesity beginning in Q1 2026.

---

The Dual-Target Rationale: Why GLP-1 + Amylin?

To appreciate amycretin's pharmacological innovation, it is essential to understand what amylin does and why combining it with GLP-1 receptor activation is mechanistically compelling.

GLP-1 Receptor Agonism (Well-Established)

GLP-1R agonism — the mechanism of semaglutide, tirzepatide, and other approved GLP-1 therapies — produces weight loss through:

• •Hypothalamic satiety signaling (reduced appetite, earlier satiation)
• •Gastric emptying delay
• •Glucose-dependent insulin secretion
• •Glucagon suppression

GLP-1R agonism has a ceiling on weight reduction, reflecting the limited scope of a single receptor pathway. Even the most effective GLP-1R agonists (semaglutide at 2.4 mg weekly) produce 15–17% weight loss — substantial, but leaving significant excess weight in most patients with severe obesity.

Amylin Receptor Agonism (The Complementary Pathway)

Amylin (also called islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to meals. Its physiological role is to:

• •Suppress postprandial glucagon secretion
• •Slow gastric emptying
• •Signal satiety via area postrema and hypothalamic neurons
• •Regulate glucose appearance from the gut

The amylin receptor (composed of calcitonin receptor + receptor activity-modifying protein subunits, primarily RAMP1-3) mediates these effects. Pramlintide, an FDA-approved amylin analog (synthetic amylin for T1D and T2D), demonstrates that amylin receptor agonism improves glycemic control and modestly reduces weight.

The key insight: GLP-1R and AMYR-1 activate different but overlapping neural circuits in the brainstem and hypothalamus. Preclinical data showed that combined GLP-1R + AMYR-1 activation produced synergistic or additive weight loss — more than either receptor pathway alone. This provided the rationale for developing a single molecule that activates both.

Why a Single Molecule Instead of Two?

Novo Nordisk already has CagriSema — a combination of weekly subcutaneous cagrilintide (amylin analog) plus semaglutide — which has shown impressive weight loss data (~25% at 68 weeks in REDEFINE 1). So why develop a single-molecule co-agonist?

1. Pharmacokinetic synchrony: A single molecule has one absorption profile, one half-life, and one route of elimination. Two co-administered drugs can have divergent PK profiles, leading to periods when one drug is at effective concentration while the other is not.

2. Oral delivery: A single co-agonist molecule can be engineered for oral absorption — something impossible with a combination of two separate peptides, each requiring individual absorption enhancement.

3. Fixed-ratio receptor activation: A single molecule guarantees a consistent GLP-1R:AMYR-1 activation ratio, whereas a combination can lead to variable relative exposure depending on individual pharmacogenomics.

4. Regulatory and manufacturing simplicity: One molecule requires one regulatory dossier, one manufacturing process, and one product label.

---

Molecular Design

Amycretin represents a significant feat of medicinal chemistry. Creating a single molecule that binds and activates two distinct receptor types with appropriate affinity and selectivity requires careful design of:

• •The binding domains: Portions of the molecule interacting with GLP-1R (typically a GLP-1 analog peptide sequence) and AMYR-1 (typically an amylin/CGRP-like sequence)
• •A linker: Connecting the two pharmacophores in a geometry that allows simultaneous receptor engagement
• •Pharmacokinetic modifications: Fatty acid chains or other modifications for albumin binding (extending half-life for once-daily or once-weekly dosing)

The specific chemical structure of amycretin has not been fully disclosed by Novo Nordisk. The compound appears to be a peptide-based co-agonist incorporating both GLP-1R and AMYR-1 pharmacophores in a single backbone — modified for oral absorption (oral formulation) or extended half-life (subcutaneous formulation).

---

Phase 1 Clinical Data: Oral Formulation

Novo Nordisk unveiled Phase 1 data for the oral formulation of amycretin at its 2024 Capital Markets Day. Key findings:

Study design: Phase 1 dose-escalation study evaluating tolerability, pharmacokinetics, and early efficacy signals of once-daily oral amycretin in individuals with obesity or overweight.

Primary efficacy finding:

• •Oral amycretin produced a mean weight loss of 13.1% from baseline after 12 weeks at the highest tolerated dose
• •For comparison, weekly semaglutide (Wegovy) produces approximately 6% weight loss at 12 weeks in trial data

Context: Phase 1 trials are designed primarily for safety and PK characterization, not efficacy confirmation. The extraordinary weight loss signal — more than double what semaglutide achieves in the same timeframe orally — generated substantial scientific excitement and media attention. Novo Nordisk leadership described it as "remarkable."

Tolerability Concerns (Oral Phase 1)

GI tolerability was a notable concern with the oral formulation:

• •87.5% of participants at the highest dose experienced gastrointestinal adverse events
• •Nausea: 75%
• •Vomiting: 56.3%
• •The vomiting events were typically limited (1–2 episodes) and nausea was classified as mild to moderate

These rates are high by conventional standards but must be interpreted in context: Phase 1 dose-escalation studies often encounter peak GI events that are substantially attenuated in later trials with refined dosing schedules and titration protocols. The question is whether GI tolerability at therapeutic doses will be manageable in Phase 3 with appropriate dose escalation.

---

Phase 1b/2a Clinical Data: Subcutaneous Formulation

The subcutaneous formulation of amycretin was evaluated in a Phase 1b/2a randomized controlled study in 125 adults with overweight or obesity (without T2D). Results were published in The Lancet (PMID: 40550231, 2025).

Design: Randomized, double-blind, placebo-controlled, dose-escalation study evaluating once-weekly subcutaneous amycretin across multiple doses over 28–36 weeks.

Efficacy results:

• •9.7% weight loss with 1.25 mg subcutaneous at 20 weeks
• •16.2% weight loss with 5 mg subcutaneous at 28 weeks
• •22% weight loss with 20 mg subcutaneous at 36 weeks
• •Placebo: 1.9–2.0% weight gain across timepoints

A critical observation: no weight loss plateau was detected at any tested dose or duration. This suggests that higher doses or longer treatment durations may produce further weight reduction — a signal consistent with amylin's complementary satiety mechanism extending beyond GLP-1R saturation.

Safety profile (subcutaneous):

• •Overall safety and tolerability consistent with the GLP-1 and amylin agonist classes
• •High frequency of GI adverse events, but rates were "similar to those seen in early-phase studies" of GLP-1 and amylin monotherapy compounds
• •No unexpected safety signals

Conclusion of Lancet publication: "Once-weekly subcutaneous amycretin up to 60 mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists, and participants achieved significantly greater weight loss across the full range of doses investigated versus placebo."

---

Differentiation from CagriSema

Researchers studying Novo Nordisk's obesity pipeline frequently ask how amycretin differs from CagriSema (cagrilintide + semaglutide). The distinctions are mechanistically significant:

Key differentiation: Amycretin's most important advantage over CagriSema is the oral formulation — if Phase 3 confirms the Phase 1 efficacy signal (13.1% weight loss at 12 weeks orally), an oral single-molecule dual agonist would represent a significant therapeutic advance. The combined weight loss efficacy of the subcutaneous formulation (up to 22% at 36 weeks) positions it competitively with the best injectable agents.

---

Differentiation from Other Obesity Drugs

Amycretin occupies a distinct mechanistic niche in the increasingly crowded obesity drug landscape:

Amycretin adds amylin receptor engagement as its mechanistic differentiator from GLP-1R-only and GLP-1R/GIPR agents — potentially offering complementary satiety signals that avoid the GLP-1R saturation ceiling.

---

Path to Phase 3

Novo Nordisk announced initiation of Phase 3 clinical trials for amycretin in Q1 2026, following positive regulatory feedback for weight management in adults with overweight or obesity. Both oral and subcutaneous formulations are being progressed.

Phase 3 design details have not been fully disclosed, but based on standard regulatory requirements for obesity trials, the trials will evaluate:

• •Primary endpoint: Change in body weight from baseline at 68–72 weeks
• •Key secondary endpoints: Proportion achieving ≥5%, ≥10%, ≥15% weight loss; cardiometabolic parameters; quality of life
• •Populations: Obesity with and without T2D in separate trials

If Phase 3 confirms the exceptional Phase 1 oral efficacy signal, amycretin could become the first drug to combine meaningful oral delivery with dual-receptor satiety synergy — a combination that has the potential to significantly expand access to GLP-1 + amylin combination therapy.

---

Researcher Interest and Open Questions

1. Will the oral efficacy signal hold at scale?

Phase 1 trials in small, carefully selected populations sometimes show exaggerated efficacy relative to later-stage trials. The critical question is whether 13.1% weight loss at 12 weeks (oral) will translate to meaningful long-term efficacy in a diverse Phase 3 population.

2. Can GI tolerability be managed?

The 87.5% GI adverse event rate with the oral formulation in Phase 1 is a concern. Careful dose titration schedules — standard in GLP-1 drug development — typically reduce GI event rates substantially from Phase 1 peak exposures. Phase 3 will clarify whether tolerability management strategies are sufficient.

3. What is the satiety synergy mechanism?

Preclinical data suggest synergy between GLP-1R and AMYR-1 pathways at the level of the brainstem area postrema and hypothalamic arcuate nucleus. The specific neuronal populations mediating this synergy — and whether they overlap with GLP-1R/GIPR synergy (tirzepatide's mechanism) — are active research questions.

4. What differentiates AMYR-1 from GIPR in the co-agonist context?

Both tirzepatide (GLP-1R/GIPR) and amycretin (GLP-1R/AMYR-1) produce weight loss beyond GLP-1R agonism alone. Are the mechanisms truly additive in the same brain circuits, or do they operate through distinct pathways? This question has implications for combination therapy design and potential future triple agonists.

5. Cardiovascular outcome data

Major GLP-1 therapies (semaglutide via SELECT, tirzepatide via SURMOUNT-MMO) have demonstrated cardiovascular risk reduction. Amycretin's CV outcomes will be an essential component of Phase 3.

---

Summary

Amycretin is Novo Nordisk's investigational single-molecule co-agonist targeting both the GLP-1 receptor and amylin receptor, available in both oral and subcutaneous formulations. Phase 1 oral data showing 13.1% weight loss in 12 weeks and Phase 1b/2a subcutaneous data showing up to 22% weight loss at 36 weeks (Lancet, 2025) established amycretin as one of the most promising next-generation obesity compounds. Its mechanistic distinction from CagriSema (single molecule vs. drug combination), from GLP-1/GIP co-agonists (amylin receptor vs. GIP receptor), and its oral formulation potential make it a unique and scientifically important compound in the metabolic disease research landscape. Phase 3 trials are underway as of 2026.

---

References

1. Amycretin Phase 1b/2a subcutaneous results. The Lancet 2025 Jun 14;405(10493):PIIS0140-6736(25)01185-7. PMID: 40550231

2. Novo Nordisk Capital Markets Day 2024: Oral amycretin Phase 1 data (13.1% weight loss at 12 weeks)

3. Novo Nordisk press release: Phase 3 initiation for amycretin (Q1 2026)

4. Pharmacy Times: "Novo Nordisk Announces Top-Line Results for Amycretin as Potential Obesity, Overweight Treatment" (2025)

5. Fierce Biotech: "Novo Nordisk hails 'remarkable' weight loss result for dual-acting oral drug in early trial" (2024)

6. Patient Care Online: "Novo's GLP-1/Amylin Dual Agonist Amycretin to Enter Late-Stage Trials for Obesity" (2025)

This article is for educational and research purposes only. Not for human use. Consult qualified healthcare professionals for clinical decisions.